Variant predominance was defined as the period when a variant accounted for ≥75% of all sequenced specimens at a site (i.e., BA.1, December 2021–March 2022** and BA.2/BA.2.12.1, March–June 2022 ††). VISION methods have been described previously ( 5) briefly, eligible medical encounters include ED/UC visits and hospitalizations among adults with COVID-19–like illness and a SARS-CoV-2 molecular test during the 14 days before through 72 hours after the encounter. The VISION Network evaluated the effectiveness of 2, 3, or 4 mRNA vaccine doses during December 2021–June 2022, a period during which different sublineages of Omicron circulated in the United States. On March 29, 2022, an additional booster dose (dose 4) was authorized for immunocompetent adults aged ≥50 years at least 4 months after dose 3 ( 4).
#BIOFIRE DIAGNOSTICS SERIES#
¶Ī 2-dose primary COVID-19 mRNA vaccination series followed by a third (booster) dose at least 5 months after dose 2 is recommended for adults aged ≥18 years without immunocompromising conditions.
Booster doses should be obtained immediately when persons become eligible. Immunocompetent persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19, including a first booster dose for all eligible persons and second booster dose for adults aged ≥50 years at least 4 months after an initial booster dose. Among adults aged ≥50 years, VE against COVID-19–associated hospitalization ≥120 days after receipt of dose 3 was 55% (95% CI = 46%–62%) and ≥7 days (median = 27 days) after a fourth dose was 80% (95% CI = 71%–85%) during BA.2/BA.2.12.1 predominance. Patterns were similar for ED/UC encounters.
The VISION network † examined 214,487 emergency department/urgent care (ED/UC) visits and 58,782 hospitalizations with a COVID-19–like illness § diagnosis among 10 states during December 18, 2021–June 10, 2022, to evaluate VE of 2, 3, and 4 doses of mRNA COVID-19 vaccines (BNT162b2 or mRNA-1273 ) compared with no vaccination among adults without immunocompromising conditions. Real-world data comparing VE during the periods when the BA.1 and BA.2/BA.2.12.1 predominated (BA.1 period and BA.2/BA.2.12.1 period, respectively) are limited. Omicron sublineages BA.2 and BA.2.12.1 emerged later and by late April 2022, accounted for most cases.* Estimates of COVID-19 vaccine effectiveness (VE) can be reduced by newly emerging variants or sublineages that evade vaccine-induced immunity ( 1), protection from previous SARS-CoV-2 infection in unvaccinated persons ( 2), or increasing time since vaccination ( 3). The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in the United States in November 2021, with the BA.1 sublineage (including BA.1.1) causing the largest surge in COVID-19 cases to date. Tenforde, MD, PhD 1 ( View author affiliations) View suggested citation Currey 15 Bruce Fireman, MA 14 Chandni Raiyani, MPH 3 Ousseny Zerbo, PhD 14 Chantel Sloan-Aagard, PhD 15 ,19 Sarah W.
Dunne, MSc 2 Kristin Goddard, MPH 14 Julie Arndorfer, MPH 9 Deepika Konatham 3 Nimish R. Kharbanda, MD 18 Akintunde Akinseye, MSPH 2 Monica Dickerson 1 Ned Lewis, MPH 14 Nancy Grisel, MPP 9 Jungmi Han 16 Michelle A. Naleway, PhD 5 Kempapura Murthy, MBBS 3 Suchitra Rao, MBBS 11 Brian E. Klein, MD, PhD 14 Emily Hartmann, MPP 15 Edward Stenehjem, MD 9 Karthik Natarajan, PhD 8 ,16 Allison L. Grannis, MD 12 ,13 Charlene McEvoy, MD 10 Palak Patel, MBBS 1 Nicola P. Irving, MHS 5 Melissa Stockwell, MD 6 ,7 ,8 Kristin Dascomb, MD, PhD 9 Malini B. Levy, PhD 2 Manjusha Gaglani, MBBS 3 ,4 Stephanie A.
0 kommentar(er)
